Lesubiz 75 Tablet SR contains Levosulpiride 75 mg as its active ingredient and is formulated as a sustained-release tablet to ensure prolonged therapeutic effect. Levosulpiride is a substituted benzamide derivative with selective dopamine D2 receptor antagonist properties, primarily acting on the gastrointestinal tract and central nervous system. It is indicated for the treatment of functional dyspepsia, gastroesophageal reflux disease (GERD), and other motility disorders of the upper gastrointestinal tract. Additionally, Levosulpiride is employed in the management of psychiatric conditions such as depression and schizophrenia due to its prokinetic and antipsychotic effects. The sustained-release formulation allows for a steady plasma concentration, improving patient compliance by reducing dosing frequency. Lesubiz 75 Tablet SR enhances gastric motility by facilitating gastric emptying and increasing lower esophageal sphincter tone, thereby alleviating symptoms like nausea, vomiting, bloating, and abdominal discomfort. It is generally well tolerated; however, potential side effects include extrapyramidal symptoms, hyperprolactinemia, and sedation. Caution is advised in patients with a history of hypersensitivity to sulpiride or related compounds, and it should be used under medical supervision, particularly in individuals with renal or hepatic impairment. Lesubiz 75 Tablet SR should be taken as prescribed to optimize therapeutic outcomes.